Leap Therapeutics, Inc. (LPTX) EPS Estimated At $-0.49

April 23, 2018 - By Clifton Ray

Analysts expect Leap Therapeutics, Inc. (NASDAQ:LPTX) to report $-0.49 EPS on May, 11.They anticipate $0.90 EPS change or 64.75 % from last quarter’s $-1.39 EPS. After having $-0.65 EPS previously, Leap Therapeutics, Inc.’s analysts see -24.62 % EPS growth. The stock decreased 4.44% or $0.33 during the last trading session, reaching $7.11. About 126,225 shares traded. Leap Therapeutics, Inc. (NASDAQ:LPTX) has declined 0.60% since April 23, 2017 and is downtrending. It has underperformed by 12.15% the S&P500.

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapeutics in cancer biology. The company has market cap of $103.10 million. The Company’s clinical stage programs include DKN-01, a monoclonal antibody targeting Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric and biliary tract cancers, as well as in Phase I clinical trial in patients with non-small cell lung cancer; and TRX518, a monoclonal antibody that is in Phase I clinical trial targeting the glucocorticoid-induced tumor necrosis factor-related receptor in patients with solid tumors. It currently has negative earnings. Leap Therapeutics, Inc. has a clinical trial collaboration agreement with Merck & Co., Inc. to investigate Leap??s DKK1 antagonist, DKN-01, in combination with Merck??s anti-PD-1 therapy, KEYTRUDA, in patients with relapsed or refractory advanced esophagogastric cancers.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.